Page 89 - 80_01

Los
medicamentos
de
origen
biotecnológico…

27.
Vaklavas
C,
Forero-­-Torres
A.
Safety
and
efficacy
of
brentuximab
vedotin
in
patients
with

Hodgkin
lymphoma
or
systemic
anaplastic
large
cell
lymphoma.
Ther
Adv
Hematol
3(4),

209-­-25
(2012).

28.
Stevens
PL,
Oluwole
O,
Reddy
N.
Advances
and
application
of
radioimmunotherapy
in
non-­-
Hodgkin
lymphoma.
Am
J
Blood
Res
2(2),
86-­-97
(2012).

29.
Chamarthy
MR,
Williams
SC,
Moadel
RM.
Radioimmunotherapy
of
non-­-Hodgkin's

lymphoma:
from
the
'magic
bullets'
to
'radioactive
magic
bullets'.
Yale
J
Biol
Med
84(4),

391-­-407
(2011).

30.
Weiss
GR,
Grosh
WW,
Chianese-­-Bullock
KA,
Zhao
Y,
Liu
H,
Slingluff
CL
Jr,
et
al.
Molecular

insights
on
the
peripheral
and
intratumoral
effects
of
systemic
high-­-dose
rIL-­-2

(aldesleukin)
administration
for
the
treatment
of
metastatic
melanoma.
Clin
Cancer
Res

17(23),
7440-­-50
(2011).

31.
Ansell
SM,
Tang
H,
Kurtin
PJ,
Koenig
PA,
Nowakowski
GS,
Nikcevich
DA,
et
al.
Denileukin

diftitox
in
combination
with
rituximab
for
previously
untreated
follicular
B-­-cell
non-­-
Hodgkin's
lymphoma.
Leukemia
26(5),
1046-­-52
(2012).

32.
Prince
HM,
Martin
AG,
Olsen
EA,
Fivenson
DP,
Duvic
M.
Denileukin
diftitox
for
the

treatment
of
CD25
low-­-expression
mycosis
fungoides
and
Sézary
syndrome.
Leuk

Lymphoma
54(1),
69-­-75
(2013).

33.
Chakraborty
A,
Tannenbaum
S,
Rordorf
C,
Lowe
PJ,
Floch
D,
Gram
H,
et
al.
Pharmacokinetic

and
pharmacodynamic
properties
of
canakinumab,
a
human
anti-­-interleukin-­-1ß

monoclonal
antibody.
Clin
Pharmacokinet
51(6),
e1-­-18
(2012).

34.
Saghafi
h,
Rahbar
K,
Nobakht
haghighi
A,
Qoreishi
M
,
Safdari
F.
Efficacy
of
Anti-­-
Interleukin-­-2
Receptor
Antibody
(Daclizumab)
in
Reducing
the
Incidence
of
Acute

Rejection
After
Renal
Transplantation.
Nephro-­-Urol
Mon
4(2),
475-­-7
(2012).

35.
Chanvillard
C,
Jacolik
RF,
Infante-­-Duarte
C,
Nayak
RC.
The
role
of
natural
killer
cells
in

multiple
sclerosis
and
their
therapeutic
implications.
Front
Immunol
4,
63
(2013).

36.
Jain
L,
Vargo
CA,
Danesi
R,
Sissung
TM,
Price
DK,
Venzon
D,
et
al.
The
role
of
vascular

endothelial
growth
factor
SNPs
as
predictive
and
prognostic
markers
for
major
solid

tumors.
Mol
Cancer
Ther
8(9),
2496-­-508
(2009).

37.
Akar
EE,
Oner
V,
Küçükerdönmez
C,
Aydin
Akova
Y.
Comparison
of
subconjunctivally

injected
bevacizumab,
ranibizumab,
and
pegaptanib
for
inhibition
of
corneal

neovascularization
in
a
rat
model.
Int
J
Ophthalmol
6(2),
136-­-40
(2013).

38.
Li
J,
Zhang
H,
Sun
P,
Gu
F,
Liu
ZL.
Bevacizumab
vs
ranibizumab
for
neovascular
age-­-related

macular
degeneration
in
Chinese
patients.
Int
J
Ophthalmol
6(2),
169-­-73
(2013).

39.
Sun
M,
Shariat
SF,
Trinh
QD,
Meskawi
M,
Bianchi
M,
Hansen
J,
et
al.
An
evidence-­-based

guide
to
the
selection
of
sequential
therapies
in
metastatic
renal
cell
carcinoma.
Ther
Adv

Urol
5(2),
121-­-8
(2013).

40.
Matsumiya
W,
Honda
S,
Kusuhara
S,
Tsukahara
Y,
Negi
A.
Effectiveness
of
intravitreal

ranibizumab
in
exudative
age-­-related
macular
degeneration
(AMD):
comparison
between

typical
neovascular
AMD
and
polypoidal
choroidal
vasculopathy
over
a
1
year
follow-­-up.

BMC
Ophthalmol
13,
10
(2013).

41.
Sabour-­-Pickett
S,
Loughman
J,
Nolan
JM,
Stack
J,
Pesudovs
K,
Meagher
KA,
et
al.
Visual

performance
in
patients
with
neovascular
age-­-related
macular
degeneration
undergoing

treatment
with
intravitreal
ranibizumab.
J
Ophthalmol
2013,
268438
(2013).

42.
Thomas
M,
Mousa
SS,
Mousa
SA.
Comparative
effectiveness
of
aflibercept
for
the
treatment

of
patients
with
neovascular
age-­-related
macular
degeneration.
Clin
Ophthalmol
7,
495-­-
501
(2013).

43.
Ohr
M,
Kaiser
PK.
Aflibercept
in
wet
age-­-related
macular
degeneration:
a
perspective

review.
Ther
Adv
Chronic
Dis
3(4),
153-­-61
(2012).

44.
Saeed
MU,
Gkaragkani
E,
Ali
K.
Emerging
roles
for
antiangiogenesis
factors
in
management

of
ocular
disease.
Clin
Ophthalmol
6,
533-­-43
(2013).

45.
Ueda
T,
Uemura
H,
Tomita
Y,
Tsukamoto
T,
Kanayama
H,
Shinohara
N,
et
al.
Efficacy
and

Safety
of
Axitinib
Versus
Sorafenib
in
Metastatic
Renal
Cell
Carcinoma:
Subgroup
Analysis

of
Japanese
Patients
from
the
Global
Randomized
Phase
3
AXIS
Trial.
Jpn
J
Clin
Oncol

43(6),
616-­-28
(2013).

46.
Busquets
N,
Carmona
L,
Surís
X.
[Systematic
review:
safety
and
efficacy
of
anti-­-TNF
in

elderly
patients].
Reumatol
Clin
7(2),
104-­-12
(2011).

47.
Smolen
JS,
Emery
P.
Infliximab:
12
years
of
experience.
Arthritis
Res
Ther
13
Suppl
1,
S2

(2011).

87